国际皮肤性病学杂志
國際皮膚性病學雜誌
국제피부성병학잡지
INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
2009年
2期
65-67
,共3页
陶小华%许恩文%胡辉%刘彤云%尚淑贤%张津萍%龚向东%王千秋
陶小華%許恩文%鬍輝%劉彤雲%尚淑賢%張津萍%龔嚮東%王韆鞦
도소화%허은문%호휘%류동운%상숙현%장진평%공향동%왕천추
奈瑟球菌,淋病%头孢曲松%抗药性%数据收集
奈瑟毬菌,淋病%頭孢麯鬆%抗藥性%數據收集
내슬구균,임병%두포곡송%항약성%수거수집
Neisseria gonorrhoeae%Ceftriaxone%Resistance%Data collection
目的 收集近期国内外发表的有关中国大陆淋球菌头孢曲松耐药监测文献,分析文献的质量及淋球菌的耐药趋势.方法 检索中国期刊全文数据库、PubMed、Cochrane数据库,筛选合格文献进行系统评价.结果 入选46篇文献,共报道10 163株淋球菌头孢曲松药敏情况.23篇文献主要来自华南(50%);26篇提供的标准菌株为WHO淋球菌分离株(56.52%);32篇文献药敏试验方法为WHO推荐的琼脂糖稀释法(69.57%);淋球菌的头孢曲松耐药率仍较低,但有增加趋势.结论 应该进一步提高淋球菌耐药监测研究的质量,使之能更好地反映淋球菌耐药状况.
目的 收集近期國內外髮錶的有關中國大陸淋毬菌頭孢麯鬆耐藥鑑測文獻,分析文獻的質量及淋毬菌的耐藥趨勢.方法 檢索中國期刊全文數據庫、PubMed、Cochrane數據庫,篩選閤格文獻進行繫統評價.結果 入選46篇文獻,共報道10 163株淋毬菌頭孢麯鬆藥敏情況.23篇文獻主要來自華南(50%);26篇提供的標準菌株為WHO淋毬菌分離株(56.52%);32篇文獻藥敏試驗方法為WHO推薦的瓊脂糖稀釋法(69.57%);淋毬菌的頭孢麯鬆耐藥率仍較低,但有增加趨勢.結論 應該進一步提高淋毬菌耐藥鑑測研究的質量,使之能更好地反映淋毬菌耐藥狀況.
목적 수집근기국내외발표적유관중국대륙림구균두포곡송내약감측문헌,분석문헌적질량급림구균적내약추세.방법 검색중국기간전문수거고、PubMed、Cochrane수거고,사선합격문헌진행계통평개.결과 입선46편문헌,공보도10 163주림구균두포곡송약민정황.23편문헌주요래자화남(50%);26편제공적표준균주위WHO림구균분리주(56.52%);32편문헌약민시험방법위WHO추천적경지당희석법(69.57%);림구균적두포곡송내약솔잉교저,단유증가추세.결론 응해진일보제고림구균내약감측연구적질량,사지능경호지반영림구균내약상황.
Objective To collect recent refefences with regard to surveillance of ceflriaxone resistance in Neisseria gonorrhoeae in mainland China,and to infer the tendency of ceftriaxone resistance.Methods References were searched in CNKI,PubMed and Cochrane databases,and eligible refefences were ineluded for systematic review.Results Forty-six refefences entered the systematic review in which 10 163 strains were reported.Of them,23 references were from South China (50%).The centrel Neisseria gonorrhoeae strains were from WHO in 26 (56.52%) references.Antimicrobial susceptibility testing was performed by agar dilution method using GC agar base recommended by WHO in 32(69.57%)refefences.The rate of ceflriaxone resistance in Neisseria gonorrhoeae in mainland China was low,but it showed an increasing tendency.Conclusion The quality of surveillance of antibiotic resistance in Neisseria gonorrhoeae should be improved in mainland China to better monitor the situation of ceflriaxone resistance.